Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 9;15(7):1447.
doi: 10.3390/ijerph15071447.

Prevalence of Vaccine Type Infections in Vaccinated and Non-Vaccinated Young Women: HPV-IMPACT, a Self-Sampling Study

Emilien Jeannot  1   2 , Manuella Viviano  3 , Charlotte de Pree  4 , Mona Amadane  5 , Emmanuel Kabengele  6 , Pierre Vassilakos  7 , Patrick Petignat  8
Affiliations

Prevalence of Vaccine Type Infections in Vaccinated and Non-Vaccinated Young Women: HPV-IMPACT, a Self-Sampling Study

Emilien Jeannot et al. Int J Environ Res Public Health. .

Abstract

Background: The human papillomavirus (HPV) vaccination program for young girls aged 11⁻26 years was introduced in Switzerland in 2008. The objective of this study was to evaluate the prevalence of high- and low-risk HPV in a population of undergraduate students using self-sampling for monitoring the HPV vaccination program's effect.

Methods: Undergraduate women aged between 18⁻31 years, attending the Medical School and University of Applied Sciences in Geneva, were invited to participate in the study. Included women were asked to perform vaginal self-sampling for HPV testing using a dry cotton swab.

Results: A total of 409 students participated in the study-aged 18⁻31 years-of which 69% of the participants were vaccinated with Gardasil HPV vaccine and 31% did not received the vaccine. About HPV prevalence, 7.2% of unvaccinated women were HPV 16 or 18 positive, while 1.1% of vaccinated women were infected by HPV 16 or 18 (p < 0.01). Prevalence of HPV 6 and 11 was 8.3% in non-vaccinated women versus 2.1% in vaccinated women (p < 0.02). We observed no cross-protection for the other HPV genotypes of a low- and high-risk strain.

Conclusions: Prevalence of HPV 6/11/16/18 was lower in vaccinated women versus unvaccinated women. Continued assessment of HPV vaccine effectiveness in real population is needed.

Keywords: HPV; self-sampling; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Human papillomavirus (HPV) genotype prevalence and distributions. In the case of multiple genotypes, each genotype was counted independently.
Figure 2
Figure 2
HPV prevalence 6/11 and 16/18, and other high-risk HPV according to vaccination status.
See this image and copyright information in PMC

References

    1. Sabeena S., Bhat P.V., Kamath V., Arunkumar G. Global human papilloma virus vaccine implementation: An update. J. Obstet. Gynaecol. Res. 2018 doi: 10.1111/jog.13634. - DOI - PubMed
    1. GLOBOCAN Estimated Cancer Incidence, Mortality and Prevalence Worldwide. [(accessed on 11 February 2018)]; Available online: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
    1. Garland S.M., Hernandez-Avila M., Wheeler C.M., Perez G., Harper D.M., Leodolter S., Tang G.W., Ferris D.G., Steben M., Bryan J., et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 2007;356:1928–1943. doi: 10.1056/NEJMoa061760. - DOI - PubMed
    1. Hall M.T., Simms K.T., Lew J.B., Smith M.A., Saville M., Canfell K. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017–2035: Example from Australia. PLoS ONE. 2018;13:e0185332. doi: 10.1371/journal.pone.0185332. - DOI - PMC - PubMed
    1. Hariri S., Bennett N.M., Niccolai L.M., Schafer S., Park I.U., Bloch K.C., Unger E.R., Whitney E., Julian P., Scahill M.W., et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States-2008–2012. Vaccine. 2015;33:1608–1613. doi: 10.1016/j.vaccine.2015.01.084. - DOI - PMC - PubMed

Substances

LinkOut - more resources